ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/02/2026
Voltar para busca
Dado oficial do USPTO
APOLLO THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
APOLLO THERAPEUTICS
ST13
US500000090798637Classe
5, 35, 36, 41, 42, 44
Pedido
90798637
Registro
7172183
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
05/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 36, 41, 42, 44
Data de depósito
28/06/2021
Data de registro
26/09/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/09/2023
Última transação
05/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
24
Localização do titular
CAMBRIDGE, GB
Examinador
MAROTTA, GABRIELLE CHRISTINA
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
APOLLO THERAPEUTICS LIMITED
APOLLO THERAPEUTICS NO.2 LLP
A. L. (pessoa física)
Representantes
Benjamin Charkow MAURIEL KAPOUYTIAN WOODS LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 36Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Therapeutic pharmaceuticals for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy in the nature of cells for medical usenamely autologous gene-engineered cells; medical preparations for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases
Classe 35
Collection of data and management of data for business purposes in connection with clinical researchtestingtrial and development of pharmaceuticalstherapeutics and medical devices; computerized database management and data processing services in the field of medicalpharmaceutical and therapeutic treatment
Classe 36
Financial sponsorship in the form of providing financial resources to non-hospital partnershipsassociations and companiesto aid in the researchdevelopmentproductionimportexportretailwholesalepromotioncommercial distribution and commercialisation of pharmaceuticaltherapeutic and medicinal products and preparations
Classe 41
Education servicesproviding instruction in the field of pharmaceutical and therapeutic medical education; arranging and conducting of conferencescongressescoursesin particular in the fields of medicine and pharmaceuticals; publishing servicesthe publication of periodicalsbooksmagazinesarticles in the field of medicinepharmaceuticalstherapeutics; publication of periodicalsbooksmagazinesarticlesin particular in the fields of medicinepharmaceuticals and therapeutics
Classe 42
Scientificmedical and pharmaceutical research and development services; clinical research in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; pharmaceutical drug development services; scientific investigations for medical purposes; medical laboratory services; laboratory research services related to pharmaceuticals; advisory services relating to medical and pharmaceutical science research in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; research and development of pharmaceutical preparations
Classe 44
Non-emergency and non-clinical medical and pharmaceutical consulting services related to the use of pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines; non-emergency medical analysis services for diagnostic and treatment purposes related to the use of pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccinesprovided by medical laboratories; medical analysis and examination services related to the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseasesprovided by medical laboratories; medical treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; advisory services relating to medical and pharmaceutical sciencemedical advisory services and pharmaceutical advisory services in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
26/11/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/09/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
26/09/2023
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
21/08/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
21/08/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
10/07/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
10/07/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2023
PUBO
PUBLISHED FOR OPPOSITION
11/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/03/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/03/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/03/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/03/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/01/2023
GNRT
NON-FINAL ACTION E-MAILED
06/01/2023
CNRT
NON-FINAL ACTION WRITTEN
06/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2022
DOCK
ASSIGNED TO EXAMINER
30/08/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/06/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
07/06/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/06/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/06/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/06/2022
GNRT
NON-FINAL ACTION E-MAILED
02/06/2022
CNRT
NON-FINAL ACTION WRITTEN
02/06/2022
DOCK
ASSIGNED TO EXAMINER
18/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/09/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/08/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/08/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/08/2021
NWAP
NEW APPLICATION ENTERED
01/07/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace APOLLO THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.